Monday - June 30, 2025

LOGIN  |  REGISTER

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 441.30
-2.10 -0.47
2.13M
257.53M
US$ 113.650B
US$ 521.00
0.00 0.00
1.44M
108.07M
US$ 56.300B
US$ 322.83
4.58 1.44
1.74M
128.98M
US$ 41.640B
US$ 560.14
-0.37 -0.07
462,101
59.80M
US$ 33.500B
US$ 106.72
0.58 0.55
489,893
239.74M
US$ 25.590B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 99.49
-2.25 -2.21
18.78M
178.90M
US$ 17.800B
US$ 35.87
0.60 1.70
3.31M
444.30M
US$ 15.940B
US$ 20.60
-0.72 -3.38
6.34M
737.45M
US$ 15.190B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 68.37
-2.43 -3.43
2.57M
192.65M
US$ 13.170B
US$ 20.50
-0.23 -1.11
1.07M
635.24M
US$ 13.020B
US$ 125.42
-1.29 -1.02
941,127
101.25M
US$ 12.700B
US$ 284.27
0.18 0.06
421,017
44.64M
US$ 12.690B
US$ 43.67
0.58 1.35
2.93M
285.58M
US$ 12.470B
US$ 55.17
1.07 1.98
2.89M
190.58M
US$ 10.510B
US$ 27.09
-0.45 -1.63
9.30M
384.82M
US$ 10.420B
US$ 172.22
-0.73 -0.42
225,207
59.81M
US$ 10.300B
US$ 44.86
-0.26 -0.58
6.35M
188.99M
US$ 8.480B
US$ 11.39
-0.21 -1.81
10.28M
727.95M
US$ 8.290B
US$ 51.84
-0.96 -1.82
2.37M
158.89M
US$ 8.240B
US$ 128.11
-0.04 -0.03
2.73M
63.53M
US$ 8.140B
US$ 93.82
-0.64 -0.68
866,711
81.83M
US$ 7.680B
US$ 73.22
-1.11 -1.49
5.26M
104.78M
US$ 7.670B
US$ 36.91
-0.60 -1.60
14.04M
184.80M
US$ 6.820B
US$ 52.21
-0.32 -0.61
11.41M
127.23M
US$ 6.640B
US$ 300.75
1.24 0.41
472,144
21.81M
US$ 6.560B
US$ 34.89
-0.65 -1.83
1.41M
186.89M
US$ 6.520B
US$ 15.71
-0.19 -1.19
113,763
411.34M
US$ 6.460B
US$ 106.90
-0.61 -0.57
792,454
60.45M
US$ 6.460B
US$ 34.63
1.10 3.28
1.81M
183.45M
US$ 6.350B
US$ 39.80
0.02 0.05
2.40M
157.90M
US$ 6.280B
US$ 36.72
-1.23 -3.24
2.09M
155.66M
US$ 5.720B
US$ 79.68
0.55 0.70
1.61M
65.62M
US$ 5.230B
US$ 103.36
0.82 0.80
916,698
48.46M
US$ 5.010B
US$ 25.77
-3.90 -13.14
4.36M
184.46M
US$ 4.750B
US$ 28.81
-0.02 -0.07
1.71M
161.80M
US$ 4.660B
US$ 29.96
-0.05 -0.17
2.02M
149.57M
US$ 4.480B
US$ 18.16
-0.24 -1.30
4.53M
236.39M
US$ 4.290B
US$ 32.58
-0.30 -0.91
3.60M
124.64M
US$ 4.060B
US$ 46.90
0.20 0.43
10.19M
85.35M
US$ 4.000B
US$ 138.88
-3.70 -2.60
392,721
28.76M
US$ 3.990B
US$ 56.19
-0.09 -0.16
2.65M
69.80M
US$ 3.920B
US$ 33.16
-0.75 -2.21
2.14M
118.01M
US$ 3.910B
US$ 62.73
1.28 2.08
863,105
61.46M
US$ 3.860B
US$ 34.74
-1.44 -3.98
755,519
108.94M
US$ 3.780B
US$ 22.12
-0.09 -0.41
2.55M
166.39M
US$ 3.680B
US$ 52.99
-0.18 -0.34
456,710
68.46M
US$ 3.630B
US$ 83.25
-0.71 -0.85
2.52M
43.12M
US$ 3.590B
US$ 65.35
0.58 0.90
1.36M
54.07M
US$ 3.530B
US$ 46.98
-0.01 -0.02
7.17M
74.39M
US$ 3.490B
US$ 29.03
-0.80 -2.68
1.05M
119.31M
US$ 3.460B
US$ 36.52
-0.60 -1.62
2.61M
92.34M
US$ 3.370B
US$ 35.81
0.33 0.93
1.45M
93.62M
US$ 3.350B
US$ 55.69
0.47 0.85
1.19M
59.60M
US$ 3.320B
US$ 47.52
0.23 0.49
917,680
63.06M
US$ 3.000B
US$ 44.12
-1.59 -3.48
3.75M
64.77M
US$ 2.860B
US$ 29.96
-0.03 -0.10
1.55M
92.74M
US$ 2.780B
US$ 9.14
-0.28 -2.97
225,230
301.94M
US$ 2.760B
US$ 16.10
-0.29 -1.77
2.06M
169.28M
US$ 2.730B
US$ 8.94
-0.18 -1.97
872,445
292.16M
US$ 2.610B
US$ 21.78
-0.11 -0.50
1.88M
119.27M
US$ 2.600B
US$ 32.40
0.20 0.62
8.79M
76.24M
US$ 2.470B
US$ 51.09
0.53 1.05
674,628
48.00M
US$ 2.450B
US$ 17.43
-0.97 -5.27
1.97M
124.39M
US$ 2.170B
US$ 114.15
-1.41 -1.22
245,812
18.90M
US$ 2.160B
US$ 27.38
0.57 2.13
2.13M
77.50M
US$ 2.120B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 41.73
0.07 0.17
1.05M
49.36M
US$ 2.060B
US$ 14.10
-0.40 -2.76
2.44M
143.92M
US$ 2.030B
US$ 16.08
0.01 0.06
1.85M
124.43M
US$ 2.000B
US$ 18.57
0.12 0.65
1.17M
107.05M
US$ 1.990B
US$ 25.95
-0.12 -0.46
849,254
76.13M
US$ 1.980B
US$ 2.70
-0.09 -3.23
11.47M
730.16M
US$ 1.970B
US$ 9.36
-0.30 -3.11
7.16M
207.13M
US$ 1.940B
US$ 33.47
-0.18 -0.53
431,209
57.03M
US$ 1.910B
US$ 43.38
-0.34 -0.78
1.30M
43.42M
US$ 1.880B
US$ 21.37
-0.92 -4.13
1.57M
86.43M
US$ 1.850B
US$ 27.98
-0.09 -0.32
166,570
65.90M
US$ 1.840B
US$ 59.04
-0.86 -1.44
28,713
30.88M
US$ 1.820B
US$ 31.98
0.15 0.47
1.13M
57.03M
US$ 1.820B
US$ 5.93
0.24 4.22
8.97M
298.81M
US$ 1.770B
US$ 18.20
0.12 0.66
3.46M
97.19M
US$ 1.770B
US$ 11.79
-0.37 -3.04
5.63M
147.58M
US$ 1.740B
US$ 13.13
0.09 0.69
717,870
131.84M
US$ 1.730B
US$ 17.11
-0.12 -0.70
4.50M
95.52M
US$ 1.630B
US$ 54.50
0.37 0.68
577,669
29.76M
US$ 1.620B
US$ 13.74
-0.66 -4.58
2.19M
117.04M
US$ 1.610B
US$ 17.97
0.06 0.34
1.13M
88.07M
US$ 1.580B
US$ 31.12
-0.90 -2.81
252,945
50.03M
US$ 1.560B
US$ 9.10
-0.41 -4.31
137,627
170.74M
US$ 1.550B
US$ 40.35
0.02 0.05
605,021
38.23M
US$ 1.540B
US$ 9.22
-0.24 -2.54
3.51M
157.22M
US$ 1.450B
US$ 22.65
-0.63 -2.71
2.28M
63.32M
US$ 1.430B
US$ 14.07
-0.67 -4.55
2.61M
101.12M
US$ 1.420B
US$ 16.80
-0.34 -1.98
2.61M
82.81M
US$ 1.390B
US$ 23.15
-0.33 -1.41
1.31M
58.63M
US$ 1.360B
US$ 20.29
-0.88 -4.16
1.53M
66.34M
US$ 1.350B
US$ 9.91
-0.03 -0.30
3.68M
131.46M
US$ 1.300B
US$ 14.77
-0.34 -2.25
2.45M
87.03M
US$ 1.290B
US$ 10.92
0.17 1.58
220,537
115.65M
US$ 1.260B
US$ 13.17
0.11 0.84
1.39M
94.69M
US$ 1.250B
US$ 19.96
-0.43 -2.11
1.83M
62.60M
US$ 1.250B
US$ 8.64
0.01 0.12
3.02M
143.18M
US$ 1.240B
US$ 11.05
3.16 40.05
6.00M
111.42M
US$ 1.230B
US$ 5.38
-0.02 -0.37
770,825
224.34M
US$ 1.210B
US$ 21.08
0.00 0.00
384,158
57.26M
US$ 1.210B
US$ 9.86
-0.09 -0.90
2.62M
117.58M
US$ 1.160B
US$ 14.33
-0.22 -1.51
1.02M
79.21M
US$ 1.140B
US$ 13.10
0.27 2.10
1.91M
84.64M
US$ 1.110B
US$ 3.64
-0.10 -2.67
6.19M
295.37M
US$ 1.080B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 3.76
-0.01 -0.27
6.65M
275.78M
US$ 1.040B
US$ 6.41
-0.09 -1.38
3.46M
160.18M
US$ 1.030B
US$ 6.67
-0.36 -5.12
2.24M
152.52M
US$ 1.020B
US$ 20.68
-0.84 -3.90
1.16M
48.86M
US$ 1.010B
US$ 9.75
0.14 1.46
3.78M
101.85M
US$ 993.040M
US$ 9.57
-0.48 -4.78
3.26M
101.77M
US$ 973.940M
US$ 11.30
0.04 0.36
3.83M
84.66M
US$ 956.660M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 17.00
-0.90 -5.03
56,995
54.23M
US$ 921.910M
US$ 15.22
-0.80 -4.99
1.33M
59.80M
US$ 910.160M
US$ 1.49
-0.04 -2.61
12.56M
604.50M
US$ 900.700M
US$ 3.69
0.00 0.00
2.93M
236.85M
US$ 873.980M
US$ 12.47
0.10 0.81
1.11M
68.88M
US$ 858.930M
US$ 30.18
0.06 0.20
810,526
27.50M
US$ 829.950M
US$ 11.64
-0.20 -1.69
1.11M
70.84M
US$ 824.580M
US$ 19.35
-0.13 -0.67
15,530
41.94M
US$ 811.540M
US$ 9.48
-0.09 -0.94
1.53M
84.82M
US$ 804.090M
US$ 43.00
-0.99 -2.25
336,347
18.64M
US$ 801.520M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 3.65
-0.09 -2.41
6.54M
218.18M
US$ 796.360M
US$ 7.10
-0.23 -3.14
4.30M
110.46M
US$ 784.270M
US$ 22.91
0.18 0.79
591,681
33.70M
US$ 772.070M
US$ 9.04
-0.26 -2.80
3.03M
85.36M
US$ 771.650M
US$ 12.50
-2.46 -16.44
9.64M
60.68M
US$ 758.500M
US$ 11.00
0.18 1.66
5,732
67.84M
US$ 746.510M
US$ 13.86
-0.36 -2.53
832,317
53.44M
US$ 740.680M
US$ 7.05
1.11 18.69
1.77M
103.80M
US$ 731.790M
US$ 10.31
-0.19 -1.81
2.33M
70.57M
US$ 727.580M
US$ 7.95
-0.55 -6.47
3.00M
91.51M
US$ 727.500M
US$ 9.33
-0.14 -1.48
1.26M
76.96M
US$ 718.040M
US$ 5.17
-0.14 -2.64
997,146
137.72M
US$ 712.010M
US$ 4.70
-0.04 -0.84
3.16M
149.08M
US$ 700.680M
US$ 22.47
-0.88 -3.77
452,103
30.43M
US$ 683.760M
US$ 13.71
-0.29 -2.07
1.35M
49.77M
US$ 682.350M
US$ 9.74
0.19 1.99
1.10M
68.38M
US$ 666.020M
US$ 5.43
-0.16 -2.86
748,356
121.55M
US$ 660.020M
US$ 9.64
-0.73 -7.04
1.42M
68.25M
US$ 657.930M
US$ 6.47
-0.02 -0.31
2.71M
100.85M
US$ 652.500M
US$ 1.93
-0.04 -2.03
15.78M
335.57M
US$ 647.650M
US$ 12.44
0.04 0.32
105,898
52.03M
US$ 647.250M
US$ 7.42
0.06 0.82
657,509
85.82M
US$ 636.780M
US$ 2.81
-0.06 -2.09
4.23M
223.27M
US$ 627.390M
US$ 11.63
-0.21 -1.77
1.05M
52.97M
US$ 616.040M
US$ 2.31
0.00 0.00
1.57M
266.12M
US$ 614.740M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 9.11
-4.27 -31.91
1.24M
65.46M
US$ 596.340M
US$ 3.13
-0.05 -1.57
1.53M
189.49M
US$ 593.100M
US$ 4.43
0.03 0.68
52,561
133.17M
US$ 589.940M
US$ 10.93
-0.01 -0.09
1.98M
53.60M
US$ 585.850M
US$ 8.14
-0.25 -2.98
1.04M
69.98M
US$ 569.640M
US$ 13.49
0.38 2.90
2.17M
42.20M
US$ 569.280M
US$ 11.41
-0.09 -0.78
1.02M
49.42M
US$ 563.880M
US$ 9.15
-0.13 -1.40
4.53M
61.17M
US$ 559.710M
US$ 6.58
0.21 3.30
6.91M
84.69M
US$ 557.260M
US$ 4.39
-0.10 -2.23
57,187
126.19M
US$ 553.970M
US$ 3.30
-0.02 -0.60
1.76M
167.38M
US$ 552.350M
US$ 11.22
0.49 4.57
820,050
49.17M
US$ 551.690M
US$ 8.77
-0.02 -0.23
890,789
62.42M
US$ 547.420M
US$ 13.49
-0.02 -0.15
935,395
40.51M
US$ 546.480M
US$ 6.33
-0.18 -2.76
8.46M
85.69M
US$ 542.420M
US$ 49.45
1.42 2.96
2.96M
10.95M
US$ 541.480M
US$ 5.01
0.09 1.83
5.91M
107.42M
US$ 538.170M
US$ 8.16
0.00 0.00
0
65.50M
US$ 534.480M
US$ 5.22
-0.08 -1.51
71,440
100.77M
US$ 526.020M
US$ 3.41
0.00 0.00
0
153.89M
US$ 524.760M
US$ 17.63
-0.52 -2.87
589,905
29.60M
US$ 521.850M
US$ 7.54
-0.26 -3.33
1.84M
68.71M
US$ 518.070M
US$ 6.61
-0.06 -0.90
745,875
78.15M
US$ 516.570M
US$ 1.69
-0.05 -2.87
13.00M
304.78M
US$ 515.080M
US$ 11.15
0.97 9.53
2.38M
45.47M
US$ 506.990M
US$ 5.62
-0.04 -0.71
1.53M
89.37M
US$ 502.260M
US$ 2.38
-0.04 -1.65
1.84M
204.94M
US$ 487.760M
US$ 9.00
-0.27 -2.91
911,026
53.38M
US$ 480.420M
US$ 6.55
-0.19 -2.82
1.23M
73.33M
US$ 480.310M
US$ 8.71
-0.10 -1.14
1.81M
54.42M
US$ 474.000M
US$ 5.80
-0.08 -1.36
26,912
81.20M
US$ 470.960M
US$ 7.40
0.22 3.06
278,374
63.35M
US$ 468.790M
US$ 10.51
-0.36 -3.31
785,252
44.40M
US$ 466.640M
US$ 12.54
0.53 4.41
423,527
37.13M
US$ 465.610M
US$ 26.81
0.06 0.22
528,624
17.36M
US$ 465.420M
US$ 6.46
0.28 4.53
729,332
71.40M
US$ 461.240M
US$ 9.10
-0.73 -7.43
959,351
50.60M
US$ 460.460M
US$ 7.76
0.01 0.13
673,103
58.23M
US$ 451.860M
US$ 4.98
-0.22 -4.23
8.10M
89.70M
US$ 447.060M
US$ 2.88
0.37 14.74
1.35M
153.83M
US$ 443.030M
US$ 5.67
-0.06 -1.05
2.55M
77.76M
US$ 440.900M
US$ 9.46
-0.15 -1.56
5.20M
45.20M
US$ 427.590M
US$ 16.54
-0.17 -1.02
387,086
25.64M
US$ 424.090M
US$ 5.03
-0.28 -5.27
11.35M
83.94M
US$ 422.220M
US$ 17.48
-0.46 -2.56
69,342
23.94M
US$ 418.470M
US$ 11.43
-0.38 -3.22
282,056
36.58M
US$ 418.110M
US$ 1.42
-0.01 -0.70
3.13M
292.87M
US$ 415.880M
US$ 8.39
-0.36 -4.11
1.11M
49.55M
US$ 415.720M
US$ 2.66
-0.14 -5.00
1.06M
155.15M
US$ 412.700M
US$ 7.10
-0.28 -3.79
818,346
53.94M
US$ 382.970M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 2.21
0.00 0.00
1.72M
171.62M
US$ 379.280M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 1.31
0.05 3.97
1.57M
282.73M
US$ 370.380M
US$ 2.20
-0.05 -2.22
968,841
167.80M
US$ 369.160M
US$ 14.01
0.05 0.36
3.17M
26.05M
US$ 364.960M
US$ 9.95
-0.07 -0.70
1.14M
36.53M
US$ 363.470M
US$ 13.33
-1.08 -7.49
901,133
27.09M
US$ 361.110M
US$ 10.75
-0.54 -4.78
1.01M
33.42M
US$ 359.260M
US$ 2.47
0.09 3.78
4.24M
141.84M
US$ 350.340M
US$ 7.24
-0.04 -0.55
209,615
47.55M
US$ 344.260M
US$ 19.48
0.72 3.84
386,934
17.61M
US$ 343.040M
US$ 4.62
0.06 1.32
2.45M
74.24M
US$ 342.990M
US$ 6.08
-0.10 -1.62
2.28M
53.81M
US$ 327.160M
US$ 7.90
0.52 7.05
118,299
41.27M
US$ 326.030M
US$ 2.14
-0.01 -0.47
4.28M
152.10M
US$ 325.490M
US$ 7.95
0.00 0.00
354,137
40.88M
US$ 325.000M
US$ 27.49
0.17 0.62
205,790
11.78M
US$ 323.830M
US$ 2.42
-0.23 -8.68
4.61M
131.16M
US$ 317.410M
US$ 6.28
-0.01 -0.16
754,153
49.95M
US$ 313.690M
US$ 1.83
-0.17 -8.50
862,449
170.55M
US$ 312.110M
US$ 0.23
-0.02 -8.00
5.82M
1.32B
US$ 303.600M
US$ 6.90
-0.19 -2.68
78,702
43.64M
US$ 301.120M
US$ 2.62
-0.09 -3.32
6.02M
114.86M
US$ 300.930M
US$ 1.31
0.01 0.77
18.91M
226.60M
US$ 296.850M
US$ 0.82
-0.11 -11.65
14.79M
361.49M
US$ 296.780M
US$ 3.25
0.00 0.00
1.68M
91.18M
US$ 296.330M
US$ 8.43
-1.30 -13.36
482,769
34.96M
US$ 294.710M
US$ 3.45
-0.08 -2.27
386,387
84.46M
US$ 291.390M
US$ 0.98
-0.05 -4.47
37.32M
291.32M
US$ 286.660M
US$ 4.60
-0.07 -1.50
777,498
61.44M
US$ 282.620M
US$ 4.78
-0.04 -0.83
625,731
58.31M
US$ 278.720M
US$ 2.15
-0.07 -3.15
5.09M
128.67M
US$ 276.640M
US$ 6.98
-0.47 -6.31
3,647
39.63M
US$ 276.620M
US$ 10.68
-0.78 -6.81
196,079
25.73M
US$ 274.800M
US$ 4.84
0.00 0.00
611,983
55.59M
US$ 269.060M
US$ 2.53
-0.06 -2.32
4.83M
106.34M
US$ 269.040M
US$ 11.36
-0.99 -8.02
1.43M
23.22M
US$ 263.780M
US$ 1.42
0.06 4.41
4.00M
185.72M
US$ 263.720M
US$ 2.71
0.01 0.37
1.60M
96.69M
US$ 262.030M
C$ 7.35
0.97 15.20
628,218
35.62M
C$ 261.810M
US$ 6.91
-0.11 -1.57
411,814
37.42M
US$ 258.570M
US$ 5.00
0.00 0.00
0
51.59M
US$ 257.950M
US$ 2.41
-0.04 -1.63
1.02M
106.59M
US$ 256.880M
US$ 3.99
-0.01 -0.25
3.94M
64.24M
US$ 256.320M
US$ 4.35
0.04 0.93
6.93M
57.94M
US$ 252.040M
C$ 3.57
-0.18 -4.80
449,693
70.31M
C$ 251.010M
US$ 5.75
-0.15 -2.54
4.92M
43.59M
US$ 250.640M
US$ 3.52
-0.09 -2.49
19.32M
71.12M
US$ 250.340M
US$ 3.89
-0.32 -7.60
6.03M
64.26M
US$ 249.970M
US$ 1.18
-0.02 -1.67
4.25M
209.67M
US$ 247.410M
US$ 7.87
-0.83 -9.54
1.70M
30.67M
US$ 241.370M
US$ 16.16
-0.34 -2.06
298,333
14.85M
US$ 239.980M
US$ 1.64
0.01 0.61
122,247
145.46M
US$ 238.550M
US$ 2.27
0.00 0.00
0
100.33M
US$ 227.750M
US$ 8.25
-0.03 -0.36
147,206
27.43M
US$ 226.300M
US$ 3.79
-0.08 -2.07
1.88M
59.55M
US$ 225.690M
US$ 8.68
0.30 3.58
11,754
25.15M
US$ 218.300M
US$ 4.90
-0.13 -2.58
1.84M
44.48M
US$ 217.950M
US$ 2.04
-0.11 -5.12
1.00M
105.91M
US$ 216.060M
US$ 5.61
5.05 903.58
68,413
38.27M
US$ 214.690M
US$ 4.53
-0.20 -4.31
6,075
47.40M
US$ 214.530M
US$ 4.70
-0.10 -2.08
183,113
44.79M
US$ 210.510M
US$ 3.15
-0.01 -0.32
1.60M
66.52M
US$ 209.540M
US$ 2.57
0.55 27.23
2.58M
81.50M
US$ 209.460M
US$ 14.43
-0.36 -2.43
248,219
14.48M
US$ 208.950M
US$ 2.98
-0.04 -1.32
75,023
70.10M
US$ 208.900M
US$ 19.26
-0.11 -0.57
117,082
10.79M
US$ 207.820M
US$ 0.94
-0.03 -3.04
22.77M
220.42M
US$ 206.090M
US$ 1.70
0.01 0.59
1.49M
121.01M
US$ 205.720M
US$ 4.27
0.00 0.00
0
48.13M
US$ 205.520M
US$ 33.60
-1.41 -4.03
389,049
6.10M
US$ 204.960M
US$ 7.32
-0.06 -0.81
7,233
27.86M
US$ 203.940M
US$ 3.57
-0.26 -6.79
143,801
56.62M
US$ 202.130M
US$ 4.50
0.28 6.64
6.97M
44.54M
US$ 200.430M
US$ 2.01
-0.08 -3.83
246,212
98.94M
US$ 198.870M
US$ 0.99
-0.03 -2.55
3.43M
197.04M
US$ 195.860M
US$ 3.70
-0.05 -1.33
248,202
52.62M
US$ 194.690M
US$ 2.39
-0.13 -5.16
1.32M
81.38M
US$ 194.500M
US$ 3.87
-0.11 -2.76
519,813
50.04M
US$ 193.650M
US$ 3.03
-0.05 -1.62
1.57M
63.81M
US$ 193.340M
US$ 4.19
-0.03 -0.71
495,204
46.03M
US$ 192.870M
US$ 4.72
-0.09 -1.87
4.78M
39.95M
US$ 188.560M
US$ 2.28
0.16 7.55
4.48M
82.55M
US$ 188.210M
US$ 3.20
-0.11 -3.32
1.22M
57.95M
US$ 185.440M
US$ 4.15
0.01 0.24
4.29M
44.51M
US$ 184.720M
US$ 8.88
-0.33 -3.58
18,519
20.52M
US$ 182.220M
US$ 3.61
-0.23 -5.99
69,225
49.91M
US$ 180.180M
US$ 2.40
-0.04 -1.64
70,361
74.11M
US$ 177.860M
US$ 3.84
-0.23 -5.65
998,548
46.23M
US$ 177.520M
US$ 2.25
-0.07 -3.02
2.52M
78.26M
US$ 176.080M
US$ 1.60
-0.18 -10.11
780,160
103.82M
US$ 166.110M
US$ 2.34
-0.11 -4.49
7.07M
70.71M
US$ 165.460M
US$ 23.58
-0.58 -2.40
421,898
6.99M
US$ 164.820M
US$ 3.02
-0.28 -8.48
1.50M
54.41M
US$ 164.320M
US$ 3.84
0.03 0.79
2.24M
42.76M
US$ 164.200M
US$ 3.33
0.02 0.60
487,620
49.09M
US$ 163.470M
US$ 2.99
0.01 0.34
1.05M
54.63M
US$ 163.290M
US$ 8.15
-0.43 -5.01
322,425
19.99M
US$ 162.920M
US$ 2.69
-0.06 -2.18
5.42M
59.74M
US$ 160.700M
US$ 2.94
0.04 1.38
1.69M
54.52M
US$ 160.290M
US$ 3.05
-0.12 -3.79
12,726
52.36M
US$ 159.700M
US$ 7.50
-0.01 -0.13
196,370
21.19M
US$ 158.930M
US$ 1.91
0.00 0.00
5,550
82.78M
US$ 158.110M
US$ 10.74
-0.09 -0.83
154,444
14.65M
US$ 157.340M
US$ 1.47
-0.09 -5.77
8.60M
107.02M
US$ 157.320M
US$ 2.13
-0.03 -1.39
191,028
72.48M
US$ 154.380M
US$ 22.97
0.80 3.61
292,595
6.53M
US$ 149.990M
US$ 4.16
-0.20 -4.59
1.26M
35.85M
US$ 149.140M
US$ 1.66
0.03 1.84
117,758
89.54M
US$ 148.640M
US$ 3.61
0.31 9.39
186,472
40.44M
US$ 145.990M
US$ 7.55
-0.16 -2.08
1.30M
19.32M
US$ 145.870M
US$ 1.45
-0.04 -2.68
75,153
100.09M
US$ 145.130M
US$ 1.48
-0.02 -1.33
1.06M
97.93M
US$ 144.940M
US$ 3.28
-0.18 -5.20
2.75M
43.17M
US$ 141.600M
US$ 9.11
-0.11 -1.19
64,932
15.53M
US$ 141.400M
US$ 2.25
-0.10 -4.26
1.43M
62.76M
US$ 141.210M
US$ 11.64
11.18 2.00
41,767
12.01M
US$ 139.800M
US$ 3.76
0.18 5.03
7,880
36.86M
US$ 138.590M
US$ 1.95
-0.08 -3.94
11.90M
70.38M
US$ 137.240M
US$ 4.12
-0.05 -1.20
502,399
33.08M
US$ 136.290M
US$ 2.40
-0.06 -2.44
4.59M
56.59M
US$ 135.820M
US$ 1.06
0.17 19.10
48.30M
124.54M
US$ 132.010M
US$ 2.96
-0.15 -4.82
94,144
44.20M
US$ 130.830M
US$ 4.20
-0.05 -1.18
6.53M
30.34M
US$ 127.430M
US$ 0.76
-0.04 -5.30
7.53M
161.56M
US$ 122.300M
C$ 1.87
0.00 0.00
25,600
64.94M
C$ 121.440M
US$ 1.04
-0.06 -5.45
3.88M
113.89M
US$ 118.450M
US$ 8.99
0.06 0.67
78,592
13.14M
US$ 118.130M
US$ 5.32
-0.96 -15.29
58.83M
22.17M
US$ 117.940M
US$ 1.66
-0.07 -4.05
566,954
70.57M
US$ 117.150M
US$ 2.12
0.06 2.91
241,485
54.92M
US$ 116.430M
US$ 5.96
0.14 2.41
877,883
19.53M
US$ 116.400M
US$ 1.55
0.08 5.44
7.58M
73.63M
US$ 114.130M
US$ 1.26
-0.09 -6.67
8.59M
90.55M
US$ 114.090M
US$ 0.54
-0.02 -2.92
3.28M
208.65M
US$ 112.880M
US$ 12.03
-0.31 -2.51
150,748
9.37M
US$ 112.720M
US$ 4.76
-0.15 -3.05
2.83M
23.61M
US$ 112.380M
US$ 0.49
-0.04 -7.23
2.89M
227.48M
US$ 112.380M
US$ 1.62
-0.03 -1.82
5.10M
69.36M
US$ 112.360M
US$ 0.88
0.0026 0.30
11.63M
125.80M
US$ 110.700M
US$ 17.31
0.23 1.35
34,095
6.36M
US$ 110.090M
US$ 3.53
0.34 10.66
2.76M
31.05M
US$ 109.610M
US$ 7.76
0.54 7.48
98,652
13.70M
US$ 106.310M
US$ 2.78
-0.20 -6.71
2.30M
37.82M
US$ 105.140M
US$ 3.22
-0.16 -4.73
101,444
32.20M
US$ 103.680M
US$ 2.99
-0.06 -1.97
111,131
34.54M
US$ 103.270M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 1.86
-0.08 -4.12
1.62M
53.33M
US$ 99.190M
US$ 2.88
-0.10 -3.36
3.14M
34.32M
US$ 98.840M
US$ 2.45
-0.07 -2.78
48,467
40.30M
US$ 98.740M
US$ 1.97
0.02 1.03
3.21M
49.81M
US$ 98.130M
US$ 5.85
-0.05 -0.85
99,956
16.71M
US$ 97.750M
US$ 1.86
-0.04 -2.11
8,099
51.37M
US$ 95.550M
US$ 1.44
-0.02 -1.37
189,570
65.88M
US$ 94.870M
US$ 7.41
-0.61 -7.61
1.05M
12.18M
US$ 90.250M
US$ 7.98
0.15 1.92
89,666
11.11M
US$ 88.660M
US$ 1.77
-0.26 -12.81
468,293
49.63M
US$ 87.850M
US$ 0.69
-0.11 -14.00
4.29M
125.56M
US$ 87.140M
US$ 1.81
-0.02 -1.15
4.81M
48.11M
US$ 87.030M
US$ 0.68
-0.04 -5.93
9.37M
127.97M
US$ 87.020M
US$ 0.73
-0.07 -9.13
7.76M
119.62M
US$ 86.840M
US$ 2.15
-0.02 -0.92
101,971
40.31M
US$ 86.670M
US$ 2.80
-0.07 -2.44
1.78M
30.48M
US$ 85.340M
US$ 0.74
0.0074 1.01
1.59M
115.21M
US$ 85.260M
US$ 7.90
0.00 0.00
79,374
10.79M
US$ 85.240M
US$ 1.92
0.02 1.05
1,518
44.27M
US$ 85.000M
US$ 1.18
-0.07 -5.60
5.96M
71.27M
US$ 84.100M
US$ 2.48
0.06 2.48
91,293
33.84M
US$ 83.920M
US$ 1.72
-0.02 -1.15
3.05M
48.10M
US$ 82.730M
US$ 5.49
-0.20 -3.51
1.41M
15.00M
US$ 82.350M
US$ 1.63
-0.07 -4.12
5.91M
48.88M
US$ 79.670M
US$ 2.30
-1.21 -34.47
12.00M
34.39M
US$ 79.100M
US$ 4.11
0.10 2.49
1.01M
19.05M
US$ 78.300M
US$ 12.25
0.84 7.36
439,214
6.39M
US$ 78.280M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 1.72
-0.02 -1.15
145,775
44.39M
US$ 76.350M
US$ 2.11
-0.14 -6.22
3.72M
36.10M
US$ 76.170M
US$ 1.25
-0.05 -3.85
5.94M
60.85M
US$ 76.060M
US$ 9.27
-0.46 -4.73
2,348
8.19M
US$ 75.920M
US$ 1.19
-0.08 -6.30
7.02M
62.76M
US$ 74.680M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 1.98
-0.02 -1.00
18,531
36.83M
US$ 72.920M
US$ 1.10
-0.05 -4.35
3.81M
65.29M
US$ 71.820M
US$ 1.94
0.03 1.57
24,553
36.18M
US$ 70.190M
US$ 1.40
-0.08 -5.41
3.98M
49.09M
US$ 68.730M
US$ 1.55
0.05 3.33
250,673
44.00M
US$ 68.200M
US$ 1.12
-0.09 -7.44
3.95M
60.08M
US$ 67.290M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
C$ 0.58
-0.03 -4.92
128,750
113.60M
C$ 65.890M
US$ 1.36
0.02 1.49
47,108
48.26M
US$ 65.630M
US$ 1.81
-0.18 -9.05
3.40M
36.24M
US$ 65.590M
C$ 2.39
-0.07 -2.85
6,484
27.40M
C$ 65.490M
US$ 1.10
-0.08 -6.78
4.67M
59.47M
US$ 65.420M
US$ 1.33
0.03 2.31
23,862
49.05M
US$ 65.240M
C$ 0.83
-0.08 -8.79
201,426
78.16M
C$ 64.870M
US$ 0.72
0.0046 0.65
767,955
90.08M
US$ 64.410M
US$ 2.31
0.01 0.43
2.36M
26.97M
US$ 62.300M
US$ 2.60
0.41 18.72
810,205
23.69M
US$ 61.590M
US$ 1.32
0.00 0.00
0
46.60M
US$ 61.510M
US$ 0.76
-0.0038 -0.50
175,440
79.97M
US$ 60.700M
US$ 0.73
-0.07 -8.14
8.38M
82.46M
US$ 60.530M
US$ 6.75
-0.04 -0.59
65,610
8.91M
US$ 60.140M
US$ 0.24
-0.0072 -2.97
1.42M
255.88M
US$ 60.130M
US$ 1.46
0.04 2.82
32,320
41.08M
US$ 59.980M
C$ 0.66
-0.09 -12.00
483,450
90.29M
C$ 59.590M
US$ 1.39
-0.02 -1.42
199,814
42.51M
US$ 59.090M
US$ 0.77
-0.04 -5.06
281,416
75.84M
US$ 58.400M
C$ 0.78
0.00 0.00
0
74.57M
C$ 58.160M
US$ 6.17
0.04 0.65
15,653
9.39M
US$ 57.940M
US$ 0.75
0.03 4.31
2.55M
77.07M
US$ 57.880M
US$ 3.10
0.05 1.64
30,477
18.29M
US$ 56.700M
C$ 0.08
0.00 0.00
0
701.73M
C$ 56.140M
US$ 1.49
-0.10 -6.29
2.83M
37.42M
US$ 55.760M
US$ 1.07
-0.03 -2.73
92,873
51.75M
US$ 55.370M
US$ 1.00
0.03 3.04
79,441
55.25M
US$ 55.250M
US$ 1.97
-0.08 -3.90
239,297
27.84M
US$ 54.840M
C$ 0.17
0.00 0.00
0
328.48M
C$ 54.200M
C$ 0.48
0.02 4.35
211,394
111.72M
C$ 53.630M
US$ 15.00
0.00 0.00
0
3.55M
US$ 53.250M
US$ 1.41
-0.04 -2.76
324,384
37.41M
US$ 52.750M
US$ 0.87
0.00 0.00
0
60.34M
US$ 52.500M
US$ 1.97
-0.02 -1.01
401,163
26.53M
US$ 52.260M
US$ 0.63
-0.04 -6.65
362,492
82.40M
US$ 51.580M
US$ 4.06
0.57 16.33
264,578
12.59M
US$ 51.120M
US$ 0.88
0.04 5.02
253,875
57.49M
US$ 50.530M
US$ 1.82
-0.03 -1.62
193,660
27.60M
US$ 50.230M
US$ 4.78
0.02 0.42
109,400
10.50M
US$ 50.190M
US$ 6.05
-1.06 -14.91
572,211
8.25M
US$ 49.910M
US$ 0.66
0.0087 1.34
238,278
75.00M
US$ 49.500M
US$ 9.81
0.00 0.00
0
5.02M
US$ 49.250M
C$ 0.69
0.01 1.47
11,000
70.89M
C$ 48.910M
US$ 1.55
0.00 0.00
0
31.24M
US$ 48.420M
US$ 0.31
-0.04 -12.63
9.26M
158.72M
US$ 48.410M
US$ 0.61
-0.07 -10.41
6.74M
79.22M
US$ 48.320M
US$ 4.97
0.00 0.00
0
9.72M
US$ 48.310M
US$ 2.32
-0.17 -6.83
2.04M
20.80M
US$ 48.260M
US$ 0.81
-0.03 -3.46
339,489
58.88M
US$ 47.580M
US$ 0.52
-0.06 -10.21
2.59M
90.56M
US$ 47.360M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 1.77
0.03 1.72
440,186
26.16M
US$ 46.300M
US$ 2.73
0.00 0.00
0
16.84M
US$ 45.970M
US$ 7.96
0.01 0.13
22,436
5.76M
US$ 45.850M
C$ 0.93
0.00 0.00
0
49.02M
C$ 45.590M
US$ 1.53
-0.17 -10.00
1.70M
29.75M
US$ 45.520M
US$ 1.02
-0.12 -10.53
3.01M
44.56M
US$ 45.450M
US$ 1.43
-0.19 -11.73
4.10M
31.20M
US$ 44.620M
C$ 0.50
0.07 16.28
1.03M
88.52M
C$ 44.260M
US$ 1.90
-0.08 -4.04
1.25M
23.23M
US$ 44.140M
US$ 0.52
-0.05 -8.56
4.75M
85.03M
US$ 44.130M
US$ 0.90
-0.10 -10.00
3.34M
47.74M
US$ 42.970M
US$ 2.48
0.00 0.00
44,736
17.06M
US$ 42.310M
US$ 1.70
-0.05 -2.97
2.37M
24.91M
US$ 42.300M
US$ 22.00
0.88 4.17
292,814
1.92M
US$ 42.240M
US$ 1.85
-0.06 -3.14
30,196
22.48M
US$ 41.590M
US$ 3.42
-0.08 -2.29
420,883
12.09M
US$ 41.350M
C$ 0.30
0.005 1.69
20,000
134.53M
C$ 40.360M
US$ 4.83
0.18 3.87
180,662
8.29M
US$ 40.040M
US$ 1.84
0.03 1.66
629,312
21.24M
US$ 39.080M
US$ 14.49
-1.06 -6.82
97,267
2.61M
US$ 37.820M
US$ 0.32
-0.06 -14.74
9.69M
116.36M
US$ 37.700M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 1.15
-0.13 -10.16
1.48M
32.60M
US$ 37.490M
US$ 1.20
-0.11 -8.40
1.40M
31.14M
US$ 37.370M
US$ 0.30
-0.03 -7.69
11.60M
123.53M
US$ 37.060M
US$ 0.92
-0.0065 -0.70
2,467
40.23M
US$ 36.850M
US$ 1.08
-0.14 -11.48
1.80M
34.08M
US$ 36.810M
US$ 1.47
-0.10 -6.37
1.77M
24.29M
US$ 35.710M
C$ 0.74
0.01 1.37
19,300
47.65M
C$ 35.260M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 1.11
0.00 0.00
1.12M
31.06M
US$ 34.480M
US$ 1.31
0.00 0.00
19,341
26.30M
US$ 34.450M
US$ 3.19
0.05 1.59
60,711
10.78M
US$ 34.390M
US$ 3.93
-0.15 -3.60
160,166
8.74M
US$ 34.370M
US$ 2.70
0.00 0.00
0
12.54M
US$ 33.860M
C$ 0.73
-0.01 -1.35
67,500
46.03M
C$ 33.600M
US$ 0.79
-0.08 -8.72
1.37M
42.18M
US$ 33.110M
US$ 4.30
0.14 3.37
363,202
7.67M
US$ 32.980M
US$ 4.44
0.17 3.98
106,703
7.30M
US$ 32.410M
US$ 6.39
-0.14 -2.14
98,237
5.04M
US$ 32.210M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 0.88
-0.06 -6.28
7,411
36.18M
US$ 31.870M
US$ 1.47
0.02 1.38
115,181
21.67M
US$ 31.850M
US$ 0.68
-0.0045 -0.66
449,576
45.72M
US$ 30.860M
US$ 1.28
-0.07 -5.19
452,352
24.00M
US$ 30.720M
US$ 1.16
-0.01 -0.94
61,227
26.47M
US$ 30.680M
US$ 1.52
0.03 2.01
768,019
20.16M
US$ 30.640M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 2.40
-0.12 -4.76
107,384
12.65M
US$ 30.360M
US$ 2.97
0.03 1.02
36,238
10.14M
US$ 30.120M
US$ 3.76
-0.16 -4.08
75,232
7.98M
US$ 30.000M
US$ 1.00
0.003 0.30
362,673
29.59M
US$ 29.530M
US$ 2.50
-0.21 -7.75
101,982
11.80M
US$ 29.500M
US$ 0.33
0.00 0.00
0
89.34M
US$ 29.390M
US$ 9.02
0.67 8.02
29,760
3.25M
US$ 29.320M
US$ 5.09
-0.01 -0.20
32,773
5.56M
US$ 28.300M
US$ 2.05
-0.12 -5.53
581,406
13.80M
US$ 28.290M
US$ 1.01
-0.01 -0.98
717,060
27.52M
US$ 27.800M
US$ 2.33
0.03 1.30
238
11.54M
US$ 26.890M
C$ 0.21
0.01 5.00
500
127.82M
C$ 26.840M
US$ 3.70
-0.17 -4.39
148,364
7.14M
US$ 26.420M
US$ 1.20
-0.01 -0.83
263,680
21.99M
US$ 26.390M
US$ 7.00
0.08 1.16
10,207
3.65M
US$ 25.550M
US$ 7.21
0.07 0.98
87,760
3.46M
US$ 24.950M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 3.57
-0.01 -0.28
119,081
6.80M
US$ 24.280M
US$ 0.31
0.003 0.97
477,055
77.45M
US$ 24.240M
C$ 0.17
0.01 6.25
568
140.03M
C$ 23.810M
US$ 1.06
-0.01 -0.93
1.46M
22.30M
US$ 23.640M
US$ 2.80
-0.14 -4.76
71,000
8.39M
US$ 23.490M
US$ 0.34
-0.02 -5.66
5.93M
66.79M
US$ 22.370M
US$ 0.38
0.0089 2.37
807,277
58.02M
US$ 22.280M
US$ 1.17
-0.02 -1.68
128,350
18.86M
US$ 22.070M
US$ 0.37
-0.01 -3.38
6.60M
59.12M
US$ 21.990M
US$ 4.62
-0.64 -12.17
160,325
4.75M
US$ 21.940M
US$ 6.76
-0.10 -1.46
15,749
3.23M
US$ 21.830M
US$ 0.62
-0.09 -13.20
2.36M
35.20M
US$ 21.750M
US$ 0.30
-0.04 -11.95
6.66M
71.01M
US$ 21.450M
US$ 0.41
-0.05 -10.30
3.78M
52.74M
US$ 21.410M
US$ 1.42
-0.20 -12.35
1.24M
14.75M
US$ 20.940M
C$ 0.14
0.00 0.00
0
148.22M
C$ 20.750M
US$ 2.37
-0.27 -10.08
108,470
8.70M
US$ 20.580M
US$ 0.33
0.001 0.30
698,788
61.77M
US$ 20.450M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 1.40
0.17 13.82
2.10M
14.35M
US$ 20.090M
US$ 5.85
-0.12 -2.01
17,877
3.41M
US$ 19.950M
US$ 1.45
0.02 1.40
60,992
13.48M
US$ 19.550M
US$ 1.08
0.00 0.00
95,963
18.06M
US$ 19.500M
C$ 0.14
0.005 3.85
55,300
140.64M
C$ 18.990M
C$ 0.04
0.00 0.00
0
541.70M
C$ 18.960M
US$ 1.33
-0.23 -14.74
727,741
14.23M
US$ 18.930M
US$ 0.05
0.00 0.00
0
407.29M
US$ 18.740M
US$ 2.80
0.11 4.09
47,865
6.66M
US$ 18.650M
US$ 1.20
-0.10 -7.69
33,100
15.49M
US$ 18.590M
US$ 10.44
0.16 1.56
45,068
1.78M
US$ 18.580M
US$ 0.61
-0.06 -9.37
783,168
30.17M
US$ 18.400M
US$ 0.55
0.04 6.77
2.52M
33.31M
US$ 18.390M
US$ 2.17
-0.05 -2.25
50,041
8.47M
US$ 18.380M
US$ 1.01
-0.02 -1.94
431,599
17.77M
US$ 17.950M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 0.94
0.0013 0.14
13,007
19.08M
US$ 17.940M
US$ 5.89
0.34 6.13
22,787
3.04M
US$ 17.910M
US$ 1.32
0.02 1.54
176,833
13.35M
US$ 17.620M
US$ 0.42
0.01 3.59
882,308
41.75M
US$ 17.580M
US$ 3.24
0.02 0.62
82,391
5.35M
US$ 17.330M
US$ 1.38
0.00 0.00
117,709
11.45M
US$ 15.800M
US$ 2.90
-0.02 -0.68
137,460
5.43M
US$ 15.750M
US$ 0.34
-0.02 -5.87
11.46M
46.58M
US$ 15.700M
US$ 0.48
-0.0049 -1.01
71,047
32.69M
US$ 15.690M
US$ 1.46
0.00 0.00
142,677
10.71M
US$ 15.640M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 1.49
-0.06 -3.87
53,828
10.17M
US$ 15.150M
US$ 0.85
-0.01 -1.23
62,098
17.55M
US$ 14.900M
US$ 1.24
0.01 0.81
8,683
11.70M
US$ 14.510M
US$ 0.33
-0.03 -7.53
200,040
41.49M
US$ 13.820M
US$ 0.33
0.0055 1.69
1.33M
41.55M
US$ 13.710M
US$ 1.56
0.23 17.22
5.53M
8.47M
US$ 13.200M
US$ 4.08
-0.02 -0.49
76,259
3.21M
US$ 13.100M
US$ 0.77
-0.01 -1.86
72,498
16.85M
US$ 12.990M
C$ 0.10
0.005 5.26
4,474
129.86M
C$ 12.990M
US$ 2.10
-0.02 -0.94
79,963
6.15M
US$ 12.920M
US$ 0.45
-0.01 -2.17
408,590
28.01M
US$ 12.600M
US$ 1.23
-0.04 -3.15
495,783
10.17M
US$ 12.510M
US$ 1.78
-0.02 -1.11
22,798
6.99M
US$ 12.440M
US$ 1.25
0.00 0.00
17,519
9.66M
US$ 12.080M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 0.30
-0.008 -2.64
314,757
38.67M
US$ 11.410M
US$ 7.00
0.20 2.94
134,158
1.63M
US$ 11.410M
C$ 0.04
0.00 0.00
546,602
280.65M
C$ 11.230M
US$ 1.61
-0.06 -3.59
59,927
6.92M
US$ 11.140M
US$ 0.31
-0.03 -8.96
267,763
35.43M
US$ 10.980M
US$ 0.74
-0.06 -7.34
857,787
14.50M
US$ 10.730M
C$ 0.11
0.02 15.79
786,430
96.40M
C$ 10.600M
US$ 1.85
0.00 0.00
4,310
5.70M
US$ 10.540M
US$ 3.34
-0.03 -0.89
705
3.12M
US$ 10.420M
US$ 0.16
0.00 0.00
0
64.53M
US$ 10.130M
US$ 0.26
-0.02 -6.33
1.61M
38.32M
US$ 10.040M
US$ 2.16
0.05 2.37
107,688
4.59M
US$ 9.910M
US$ 2.15
-0.03 -1.38
28,439
4.58M
US$ 9.850M
US$ 0.11
-0.0029 -2.59
30,136
88.13M
US$ 9.610M
US$ 0.40
0.07 20.37
6.10M
23.13M
US$ 9.250M
US$ 1.68
-0.08 -4.29
64,479
5.43M
US$ 9.100M
US$ 0.96
0.01 1.05
808,657
9.44M
US$ 9.060M
US$ 2.17
-0.04 -1.81
225,205
4.17M
US$ 9.050M
US$ 2.90
-0.13 -4.29
68,152
3.00M
US$ 8.700M
US$ 0.67
-0.02 -3.04
1.35M
12.85M
US$ 8.600M
US$ 0.43
-0.05 -10.25
882,510
19.49M
US$ 8.380M
C$ 0.02
0.00 0.00
0
418.56M
C$ 8.370M
US$ 5.13
0.11 2.19
64,392
1.60M
US$ 8.210M
US$ 1.35
0.18 15.38
3.37M
6.03M
US$ 8.140M
US$ 3.00
0.19 6.76
138,243
2.71M
US$ 8.130M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 1.13
-0.04 -3.42
1.00M
6.90M
US$ 7.800M
US$ 3.47
-0.33 -8.68
69,902
2.23M
US$ 7.740M
C$ 0.03
0.00 0.00
0
308.61M
C$ 7.720M
US$ 2.79
0.25 9.84
465,905
2.76M
US$ 7.700M
C$ 0.06
0.005 10.00
178,000
137.51M
C$ 7.560M
US$ 1.45
-0.22 -13.17
1,293
5.17M
US$ 7.500M
US$ 2.12
0.17 8.72
4,599
3.47M
US$ 7.360M
US$ 1.03
-0.02 -1.90
10,706
6.97M
US$ 7.180M
US$ 6.51
0.10 1.56
8,490
1.10M
US$ 7.160M
US$ 0.51
0.02 5.14
261,475
14.09M
US$ 7.140M
US$ 0.73
0.02 2.82
2.02M
9.39M
US$ 6.850M
US$ 0.22
0.00 0.00
0
30.74M
US$ 6.850M
C$ 0.15
0.005 3.45
118,832
44.79M
C$ 6.720M
US$ 1.04
0.01 0.97
425,369
6.10M
US$ 6.340M
US$ 0.75
-0.08 -9.15
519,456
8.36M
US$ 6.230M
US$ 5.54
-0.42 -7.05
74,542
1.12M
US$ 6.200M
US$ 1.06
-0.03 -2.75
693,045
5.70M
US$ 6.040M
US$ 2.34
0.01 0.43
21,004
2.58M
US$ 6.040M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 0.22
-0.005 -2.18
2.37M
25.92M
US$ 5.810M
US$ 3.70
-0.29 -7.27
140,417
1.54M
US$ 5.700M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 7.97
-0.24 -2.87
14,062
696,249
US$ 5.550M
US$ 2.30
-0.14 -5.74
16,864
2.30M
US$ 5.290M
US$ 0.02
0.00 0.00
0
261.79M
US$ 5.240M
US$ 1.43
0.00 0.00
75,297
3.65M
US$ 5.220M
US$ 0.97
-0.02 -1.92
58,674
5.35M
US$ 5.190M
US$ 1.43
0.00 0.00
0
3.41M
US$ 4.880M
US$ 9.58
-0.57 -5.62
288,551
505,798
US$ 4.850M
US$ 0.32
0.02 6.67
5.63M
15.10M
US$ 4.830M
US$ 2.70
-0.09 -3.23
84,806
1.75M
US$ 4.720M
US$ 0.92
-0.02 -2.34
205,076
5.09M
US$ 4.680M
US$ 0.04
-0.005 -11.11
100
112.91M
US$ 4.520M
US$ 3.42
-0.08 -2.29
36,214
1.32M
US$ 4.510M
US$ 3.06
-0.17 -5.26
299,622
1.46M
US$ 4.470M
US$ 1.00
0.02 2.13
621,212
4.43M
US$ 4.430M
US$ 2.75
0.00 0.00
0
1.61M
US$ 4.430M
US$ 0.30
-0.04 -10.61
410
14.89M
US$ 4.390M
US$ 0.34
0.05 16.21
100
12.27M
US$ 4.130M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 0.45
-0.006 -1.32
1.34M
8.99M
US$ 4.050M
US$ 4.40
0.00 0.00
4,071
914,234
US$ 4.020M
US$ 0.89
0.0074 0.84
108,991
4.38M
US$ 3.890M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 1.80
0.04 2.44
77,093
1.93M
US$ 3.480M
US$ 0.78
0.01 1.30
85,573
4.34M
US$ 3.390M
US$ 1.12
-0.03 -2.61
54,424
3.01M
US$ 3.370M
US$ 1.33
-0.04 -2.92
362,818
2.51M
US$ 3.340M
US$ 0.31
0.0022 0.72
314,384
10.83M
US$ 3.340M
US$ 0.26
-0.0019 -0.73
3.24M
12.48M
US$ 3.240M
US$ 0.74
0.04 5.71
463,179
4.19M
US$ 3.100M
US$ 0.95
0.11 13.10
212,290
3.22M
US$ 3.060M
US$ 2.78
-0.68 -19.65
222,059
1.09M
US$ 3.030M
US$ 0.18
0.00 0.00
0
16.39M
US$ 3.000M
US$ 1.81
0.02 1.12
206,529
1.66M
US$ 3.000M
US$ 0.07
0.002 2.86
387,765
41.30M
US$ 2.970M
US$ 0.61
0.006 1.00
65,544
4.89M
US$ 2.960M
US$ 2.24
0.02 0.90
34,966
1.30M
US$ 2.910M
US$ 2.45
-0.14 -5.41
48,704
1.17M
US$ 2.870M
US$ 0.64
0.0046 0.73
340,484
4.48M
US$ 2.850M
US$ 3.55
0.01 0.28
3,288
736,431
US$ 2.610M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 3.44
-0.02 -0.66
521,065
724,152
US$ 2.490M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
US$ 1.85
0.03 1.65
31,161
1.28M
US$ 2.370M
US$ 0.34
-0.13 -27.63
14.56M
6.47M
US$ 2.200M
US$ 0.30
0.00 0.00
0
7.24M
US$ 2.170M
US$ 0.33
-0.02 -5.37
1.07M
6.29M
US$ 2.080M
US$ 2.28
-0.19 -7.69
115,787
852,996
US$ 1.940M
US$ 0.70
-0.01 -1.42
365,755
2.77M
US$ 1.940M
US$ 0.003
0.00 0.00
1.30M
635.88M
US$ 1.910M
C$ 0.07
0.00 0.00
0
27.30M
C$ 1.910M
US$ 0.22
-0.01 -4.70
1.62M
8.51M
US$ 1.900M
US$ 0.32
-0.05 -14.08
23.42M
5.90M
US$ 1.860M
US$ 0.05
-0.005 -9.09
178,392
36.47M
US$ 1.820M
C$ 0.02
0.00 0.00
0
121.27M
C$ 1.820M
US$ 0.006
0.001 20.00
3
302.90M
US$ 1.820M
US$ 0.71
0.03 4.80
450,794
2.51M
US$ 1.790M
US$ 0.37
-0.07 -14.94
440,105
4.75M
US$ 1.760M
US$ 0.71
-0.06 -7.79
65,457
2.25M
US$ 1.600M
US$ 0.03
0.00 0.00
39,000
54.39M
US$ 1.580M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
C$ 0.01
0.00 0.00
0
141.96M
C$ 1.420M
US$ 0.98
-0.01 -1.01
416,951
1.44M
US$ 1.410M
US$ 1.02
-0.01 -0.97
316,787
1.30M
US$ 1.330M
US$ 0.80
-0.01 -1.48
55,823
1.60M
US$ 1.280M
US$ 0.10
0.00 0.00
0
12.23M
US$ 1.250M
US$ 0.60
0.02 3.07
268,072
2.04M
US$ 1.230M
US$ 0.43
-0.0092 -2.09
131,052
2.78M
US$ 1.200M
US$ 0.97
0.07 7.22
4,231
1.21M
US$ 1.170M
C$ 0.03
0.00 0.00
0
38.74M
C$ 1.160M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.31
-0.01 -3.73
4.20M
3.19M
US$ 989K
US$ 0.20
0.00 0.00
0
4.85M
US$ 985K
US$ 0.76
0.03 3.41
226,800
1.27M
US$ 964K
US$ 1.11
0.10 9.90
100
863,788
US$ 959K
US$ 0.02
0.00 0.00
0
47.10M
US$ 942K
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
C$ 0.10
0.00 0.00
0
8.86M
C$ 886K
US$ 0.03
0.00 0.00
0
29.49M
US$ 826K
US$ 0.05
0.00 0.00
0
14.37M
US$ 719K
US$ 0.02
0.002 12.50
600
39.74M
US$ 715K
US$ 0.11
0.00 0.00
0
6.58M
US$ 705K
US$ 0.16
-0.008 -4.71
200
4.31M
US$ 698K
US$ 0.20
-0.04 -17.30
8.36M
3.27M
US$ 644K
US$ 0.09
0.0023 2.62
23,756
6.96M
US$ 626K
US$ 0.02
-0.007 -24.14
961,084
26.83M
US$ 590K
US$ 0.87
-0.06 -6.21
267,145
580,840
US$ 505K
US$ 0.24
0.00 0.00
0
2.05M
US$ 494K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.09
0.0034 4.12
46.77M
3.93M
US$ 338K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.21
0.00 0.00
0
1.39M
US$ 292K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.008
0.0017 26.98
5.92M
34.87M
US$ 279K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.003
0.00 0.00
0
61.76M
US$ 185K
US$ 0.001
0.00 0.00
0
18.98M
US$ 19K
US$ 0.002
0.00 0.00
0
4.87M
US$ 10K
US$ 0.07
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
100.08M
US$ -
US$ 0.15
0.00 0.00
52,969
-
US$ -
US$ 0.00
0.00 0.00
0
44.57M
US$ -
US$ 0.00
0.00 0.00
0
54.52M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.70M
US$ -
US$ 0.00
0.00 0.00
0
3.14M
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
10.88M
US$ -
US$ 0.00
0.00 0.00
0
42.08M
US$ -
US$ 0.00
0.00 0.00
0
71.42M
US$ -
US$ 0.00
0.00 0.00
0
5.12B
US$ -
US$ 0.00
0.00 0.00
0
172.20M
US$ -
US$ 0.00
0.00 0.00
0
514.01M
US$ -
US$ 0.24
0.00 0.00
65,403
-
US$ -
US$ 1.27
-0.02 -1.56
112,706
-
US$ -
C$ 0.50
0.00 0.00
0
-
C$ -
US$ 4.91
-0.20 -3.91
13,944
-
US$ -

Latest Biotechnology Stock News


Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape. A... Read more


argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company... Read more


Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

ROCKVILLE, Md. & EDMONTON, Alberta / Jun 29, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available... Read more


Quantum BioPharma Announces Private Placement

TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A multiple voting shares (“MVS”) at a price of $50 per MVS, for aggregate gross proceeds of up to $600 (the “Offering”). The Company... Read more


Pliant Therapeutics Provides Update on BEACON-IPF

Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary... Read more


Exicure Reports First Quarter 2025 Financial Results

REDWOOD CITY, Calif. / Jun 27, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter... Read more


Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch

Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce Croom has joined Hemostemix as its Chief Commercialization Officer, and partnered to offer MCI Screen through Hemostemix. MCI Screen is an FDA-approved and insurer-reimbursed advanced cognitive test for Vascular Dementia. Clinically, ACP-01 has been observed to reverse vascular... Read more


Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Hadassah-University Medical Center, Jerusalem, Israel, as a new clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a... Read more


Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease

Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placebo Findings to be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress SAN DIEGO, June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in both... Read more


Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

SEATTLE / Jun 27, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients... Read more


Ainos and ASE Technology Broaden Strategic Partnership to Target Deploy Up to 15,000 AI Nose Across Key Sites

Relationship Broadens Scope to Key ASE and SPIL Facilities with Multi-Phase Deployment Milestone Positions ASEH and Ainos as First-Mover in AI-Powered Scent Intelligence for the Semiconductor Industry SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 27, 2025 / Ainos, Inc. (NASDAQ:AIMD) (NASDAQ:AIMDW) ("Ainos" or the "Company") , a leader in AI-driven scent digitization, today announced the expansion of its strategic relationship with ASE Technology Holding Co., Ltd.... Read more


Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cance... Read more


Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants WATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that... Read more


Ultragenyx Pharmaceutical Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for GTX-102 (apazunersen) as a treatment for Angelman syndrome. "FDA Breakthrough... Read more


HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series by HonorHealth Research Institute on June 27, 2025 in Scottsdale, Arizona MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based... Read more


Turnstone Biologics Enters into Agreement to be Acquired by XOMA Royalty for $0.34 in Cash Per Share Plus a Contingent Value Right

EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into a definitive merger agreement (“the Merger Agreement”), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock (“Turnstone common stock”) plus one non-transferable... Read more


InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded... Read more


BioCryst Pharmaceuticals Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from... Read more


Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Canc

BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines’ daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic... Read more


Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National... Read more


Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company’s newly designated Series C Convertible Preferred Stock (the “Preferred Stock”). Pursuant to the Purchase Agreement, Blue Harbour purchased... Read more


Cidara Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per... Read more


ProQR Therapeutics Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025 Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing... Read more


Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development... Read more


Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation

Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s efficacy, safety, and tolerability profile SEATTLE and VANCOUVER, British Columbia, June... Read more


CorMedix Announces Proposed Public Offering of Common Stock

BERKELEY HEIGHTS, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it intends to offer and sell $85.0 million of shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by CorMedix. In addition, CorMedix intends to grant the u... Read more


INmune Bio to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025 Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, will host a conference call on Monday, June 30 beginning at 8:00am EDT to present top line data from the Phase 2 MINDFuL trial in early Alzheimer’s Disease. MINDFuL Results Call Information: To participate in this... Read more


Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

MOUNTAIN VIEW, Calif. / Jun 26, 2025 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET. Mr. Albanna will discuss Aditxt’s innovation acceleration business model, overview and status of Aditxt’s two programs... Read more


Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano,... Read more


Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting

JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily... Read more


Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Phase 3 Top Line Results Expected Q2 2026 SALT LAKE CITY, June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the first patient has been dosed in its pivotal Phase 3 clinical trial of LPCN 1154 (oral brexanolone), its investigational oral treatment for postpartum depression (PPD). Following FDA feedback,... Read more


Annovis Bio to Attend the AAIC 2025 with Four Poster Presentations

MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present... Read more


Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata Therapeutics’ Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic...

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group Cohort B data corroborate Cohort A data indicating certepetide has a treatment effect and an attractive safety profile Full study data from both cohorts expected later this year BARCELONA, Spain, June 26, 2025... Read more


Arcutis Biotherapeutics’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation reflects ZORYVE’s proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitor Among newly evaluated branded topical therapies, ZORYVE is the only treatment with a strong recommendation for adults with mild... Read more


BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participation CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and... Read more


Avalon GloboCare and Qi Diagnostics Enter into Definitive Agreement to Co-Develop Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

FREEHOLD, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that it entered into a definitive agreement with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. Through this strategic col... Read more


GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 patients evaluated 6-week interim biomarker data (n=24) expected in July 2025 and topline data expected in Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with... Read more


ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease...

Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for kidney disease addressing renal lipotoxicity. There are no available drugs targeting renal lipotoxicity that damages the kidneys’ filtration system, causing protein leakage into the urine (proteinuria) and disease progression. VAR 200, designed to alleviate renal lipid accumulation, has preclinical data in three types of kidney disease (DKD,... Read more


Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control  ALTO-203, a non-stimulant compound which demonstrated pro-cognitive and wake-promoting effects, has the potential to address sustained attention abnormalities in EEG biomarker characterized patients  Pharmacodynamic activity is aligned with the proposed mechanism of ALTO-203; improvements in attention... Read more


BridgeBio Pharma to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio. Dr.... Read more


Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous... Read more


Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for... Read more


Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infectio

Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate and largely related to injection site and infusion reactions with no serious or severe adverse events observed Following a single dose, serum concentrations of VYD2311 remained high at six months with an observed half-life of the IM dose route having the longest duration at... Read more


KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada Pendopharm brings proven track record in commercializing innovative therapies across multiple therapeutic areas with capabilities to launch sebetralstat in Canadian market CAMBRIDGE, Mass. & SALISBURY, England / Jun 26, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted... Read more


Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® at medical conferences and a planned KOL event MDNA11 continues to exhibit compelling deep and durable anti-tumor activity in difficult-to-treat solid tumors with best-in-class potential relative to competing IL-2 programs Results presented at the 2025 AACR showed response... Read more


Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada... Read more


Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

LEXINGTON, Mass. / Jun 26, 2025 / Business Wire / Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration (FDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently lacking FDA-approved therapy. “Primary vitreoretinal lymphoma is... Read more


Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss... Read more


CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025 Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026 Preclinical in vivo cardiovascular... Read more


I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated results to be presented at ESMO GI on July 2nd Company to host investor event on July 8th ROCKVILLE, Md., June 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech... Read more